{"entity":{"id":"nct06483555","kind":"trial","name":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel","aka":["PANGEA"],"tldr":"A phase 1/2 trial of gemcitabine, nab-paclitaxel, erlotinib, nALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) and other drugs in pancreatic cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.","summary":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel is a phase 1/2, interventional study registered as NCT06483555 by UNC Lineberger Comprehensive Cancer Center, with a registry enrolment figure of 104 participants, started 2025-02-06 and due to reach its primary completion in 2027-08. Interventions recorded: Gemcitabine; Nab paclitaxel; Erlotinib; NALIRIFOX; Folfirinox. Conditions listed: Pancreatic Adenocarcinoma; Metastatic Pancreatic Cancer; Basal Cell Neoplasm. Primary outcome: Adverse Events per Common Terminology Criteria for Adverse Events (NCI-CTCAE); Dose-limiting toxicity (DLT); Overall survival- classical metastatic pancreatic adenocarcinoma. Pancreatic eligibility wording from the registry: \"* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 Histological or cytological evidence/confirmation of unresectable, borderline resectable, or metastatic (basal-like and classical) pancreatic adenocarcinoma\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06483555","url":"https://clinicaltrials.gov/study/NCT06483555"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["gemcitabine","nab-paclitaxel","erlotinib","nalirifox","folfirinox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06483555","phase":"1/2","setting":"Subjects With Advanced Basal-like Pancreatic Adenocarcinoma Treated With Gemcitabine, Erlotinib and Nab-paclitaxel (PANGEA) Versus Subjects With Classical Pancreatic Adenocarcinoma Treated With Triplet Standard of Care Therapy.","sponsor":"UNC Lineberger Comprehensive Cancer Center","enrolled":104,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06483555/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/"},{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"nalirifox","kind":"drug","name":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)","route":"/drugs/nalirifox/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}